GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at
GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at the European Lung Cancer Conference. Alessandra Curioni Fontecedro MD, a senior physician in the department of oncology at University Hospital, Zurich explained to Oncology Times reporter Peter Goodwin how the molecular signatures of sensitivity to therapies targeting checkpoint inhibition pathways were not disturbed by prior chemotherapy.